Back to results
US 10,307,464 B2Granted
Use of ultrarapid acting insulin
AssigneeMannKind Corporation
InventorsAnders Hasager Boss, Richard Petrucci
Life of this patent
Estimating the term…
Abstract
Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
Claims12
A method of treating pre-meal hyperglycemia in a patient in need of treatment who is monitored for pre-meal blood glucose levels for 10 days comprising:
- regularly administering a split dose of an ultra rapid acting insulin formulation, the split dose including an initial dose taken at mealtime and a second dose of between 10% to 100% of the initial dosage taken 30 to 150 minutes after beginning a meal;
- wherein when pre-meal blood glucose level for a next meal had been regularly greater than 120 mg/dl.
A method of treating hyperglycemia in a patient whose pre-meal blood glucose is greater than 140 mg/dl, comprising:
- administering a mealtime dose, then administering a secondary dose of an ultra rapid acting insulin formulation 30 to 120 minutes after the mealtime dose comprising between 10% to 100% of an initial dose, wherein the secondary dose is titrated so that median blood glucose 1 to 2 hours after the secondary dose is less than 180 mg/dl.
Dependencies are inferred from the claim text.